WordNet

any of a large group of nitrogenous organic compounds that are essential constituents of living cells; consist of polymers of amino acids; essential in the diet of animals for growth and for repair of tissues; can be obtained from meat and eggs and milk and legumes; "a diet high in protein"
the 22nd letter of the Roman alphabet (同)v
a gene that disposes normal cells to change into cancerous tumor cells (同)transforming_gene

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 未分化リンパ腫キナーゼ（ALK）融合癌遺伝子陽性非小細胞肺癌 anaplastic lymphoma kinase alk fusion oncogene positive non small cell lung cancer
2. 甲状腺結節および非髄様甲状腺癌におけるオンコジーンおよび腫瘍抑制遺伝子 oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer
3. 慢性骨髄性白血病の細胞生物学および分子生物学 cellular and molecular biology of chronic myeloid leukemia
4. 進行非小細胞肺癌に対する遺伝子型による個別治療 personalized genotype directed therapy for advanced non small cell lung cancer
5. 前立腺癌の分子生物学 molecular biology of prostate cancer

In vivo evidence for epidermal growth factor receptor (EGFR)-mediated release of prolactin from the pituitary gland.

Dahlhoff M, Blutke A, Wanke R, Wolf E, Schneider MR.SourceInstitute of Molecular Animal Breeding and Biotechnology, Gene Center, LMU Munich, Munich 81377, Germany.
The Journal of biological chemistry.J Biol Chem.2011 Nov 11;286(45):39297-306. Epub 2011 Sep 13.
Members of the epidermal growth factor receptor (EGFR/ERBB) system are essential local regulators of mammary gland development and function. Emerging evidence suggests that EGFR signaling may also influence mammary gland activity indirectly by promoting the release of prolactin from the pituitary gl
PMID 21914800

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

Ioannou N, Dalgleish AG, Seddon AM, Mackintosh D, Guertler U, Solca F, Modjtahedi H.SourceSchool of Life Sciences, Kingston University London, Kingston-upon-Thames, Surrey KT1 2EE, UK.
British journal of cancer.Br J Cancer.2011 Nov 8;105(10):1554-62. doi: 10.1038/bjc.2011.396. Epub 2011 Oct 4.
BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. However, duration of response is often limited and there is currently no reliable predi
PMID 21970876